Par Drugs and Chemicals Past Earnings Performance
Past criteria checks 5/6
Par Drugs and Chemicals has been growing earnings at an average annual rate of 25.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 17.1% per year. Par Drugs and Chemicals's return on equity is 18.1%, and it has net margins of 14.6%.
Key information
25.6%
Earnings growth rate
24.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 17.1% |
| Return on equity | 18.1% |
| Net Margin | 14.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13Revenue & Expenses BreakdownBeta
How Par Drugs and Chemicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 973 | 142 | 53 | 0 |
| 30 Sep 23 | 962 | 127 | 52 | 0 |
| 30 Jun 23 | 952 | 115 | 51 | 0 |
| 31 Mar 23 | 957 | 113 | 49 | 0 |
| 31 Dec 22 | 933 | 103 | 46 | 0 |
| 30 Sep 22 | 873 | 106 | 42 | 0 |
| 30 Jun 22 | 821 | 91 | 42 | 0 |
| 31 Mar 22 | 751 | 92 | 41 | 0 |
| 31 Dec 21 | 692 | 112 | 41 | 0 |
| 30 Sep 21 | 686 | 112 | 41 | 0 |
| 30 Jun 21 | 631 | 115 | 40 | 0 |
| 31 Mar 21 | 608 | 116 | 40 | 0 |
| 31 Dec 20 | 579 | 88 | 38 | 0 |
| 30 Sep 20 | 550 | 83 | 38 | 0 |
| 30 Jun 20 | 554 | 65 | 40 | 0 |
| 31 Mar 20 | 558 | 48 | 41 | 0 |
| 31 Dec 19 | 532 | 41 | 38 | 0 |
| 30 Sep 19 | 506 | 20 | 36 | 0 |
| 30 Jun 19 | 484 | 23 | 36 | 0 |
| 31 Mar 19 | 463 | 25 | 36 | 0 |
| 31 Mar 18 | 424 | 15 | 35 | 0 |
| 31 Mar 17 | 488 | 18 | 33 | 0 |
| 31 Mar 16 | 333 | 4 | 22 | 0 |
Quality Earnings: PAR has high quality earnings.
Growing Profit Margin: PAR's current net profit margins (14.6%) are higher than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PAR's earnings have grown significantly by 25.6% per year over the past 5 years.
Accelerating Growth: PAR's earnings growth over the past year (38%) exceeds its 5-year average (25.6% per year).
Earnings vs Industry: PAR earnings growth over the past year (38%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: PAR's Return on Equity (18.1%) is considered low.